Cargando…

Topoisomerase I expression is associated with prognosis in postoperative non‐small cell lung cancer patients

BACKGROUND: Biomarkers may help to improve non‐small cell lung cancer (NSCLC) prognosis. However, the prognostic effect of topoisomerase I (Topo I) on NSCLC is unknown. We evaluated the clinicopathologic and prognostic significance of tumor Topo I and thymidylate synthase (TS) protein expression in...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lu, Baohua, Zhang, Hongmei, Zhang, Tongmei, Cai, Yiran, Hu, Ying, Zheng, Hua, Li, Baolan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley & Sons Australia, Ltd 2016
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4930970/ https://www.ncbi.nlm.nih.gov/pubmed/27385993 http://dx.doi.org/10.1111/1759-7714.12359

Ejemplares similares

Survival Analysis of 159 Patients With Advanced Non-Small-Cell Lung Cancer Resistant to First-Generation Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor
por: Hu, Aimin, et al.
Publicado: (2023)

Hyaluronic Acid Correlates With Bone Metastasis and Predicts Poor Prognosis in Small-Cell Lung Cancer Patients
por: Zhao, Cong, et al.
Publicado: (2022)

Post-therapeutic circulating tumor cell-associated white blood cell clusters predict poor survival in patients with advanced driver gene-negative non-small cell lung cancer
por: Wang, Ying, et al.
Publicado: (2023)

Beneficial effects of postoperative radiotherapy for IIIA‑N2 non‑small cell lung cancer after radical resection analysed using the propensity score‑matching method
por: Tian, Cuimeng, et al.
Publicado: (2023)

Trichomegaly and scalp hair changes following treatment with erlotinib in pulmonary adenocarcinoma patients: A case report and literature review
por: Zheng, Hua, et al.
Publicado: (2016)

Investigating the mechanism by which SMAD3 induces PAX6 transcription to promote the development of non-small cell lung cancer
por: Qian, Zhe, et al.
Publicado: (2018)

A single center analysis of first-line treatment in advanced KRAS mutant non-small cell lung cancer: real-world practice
por: Liu, Yanxia, et al.
Publicado: (2022)

Plasma hepatocyte growth factor as a noninvasive biomarker in small cell lung cancer
por: Zhao, Cong, et al.
Publicado: (2023)

Postoperative Radiotherapy for Patients with Completely Resected Pathological Stage IIIA-N2 Non-small Cell Lung Cancer: A Preferential Benefit for Squamous Cell Carcinoma
por: Tian, Cuimeng, et al.
Publicado: (2020)

The relationship between the preoperative plasma level of HIF-1α and clinic pathological features, prognosis in non-small cell lung cancer
por: He, Jiabei, et al.
Publicado: (2016)

Mutation status analysis of 58 patients with advanced ALK fusion gene positive non small cell lung cancer
por: Yang, Yuan, et al.
Publicado: (2023)

Comprehensive Comparative Molecular Characterization of Young and Old Lung Cancer Patients
por: Hu, Mingming, et al.
Publicado: (2022)

Phase I study of sequentially administered topoisomerase I inhibitor (irinotecan) and topoisomerase II inhibitor (etoposide) for metastatic non-small-cell lung cancer.
por: Ando, M., et al.
Publicado: (1997)

Topoisomerase II alpha expression and the benefit of adjuvant chemotherapy for postoperative patients with non-small cell lung cancer
por: Yan, Shi, et al.
Publicado: (2010)

Mining expression and prognosis of topoisomerase isoforms in non-small-cell lung cancer by using Oncomine and Kaplan–Meier plotter
por: Hou, Guo-Xin, et al.
Publicado: (2017)

Vimentin expression in circulating tumor cells (CTCs) associated with liver metastases predicts poor progression-free survival in patients with advanced lung cancer
por: Wang, Ying, et al.
Publicado: (2019)

Gene Mutation Analysis and Quantitation of DNA Topoisomerase I in Previously Untreated Non‐small Cell Lung Carcinomas
por: Takatani, Hiroshi, et al.
Publicado: (1997)

Small DNA circles as bacterial topoisomerase I inhibitors
por: Li, Dawei, et al.
Publicado: (2019)

Analysis of topoisomerase I expression and identification of predictive markers for efficacy of topotecan chemotherapy in small cell lung cancer
por: Lv, Chunxin, et al.
Publicado: (2018)

Development of PD-1/PD-L1 Pathway in Tumor Immune Microenvironment and Treatment for Non-Small Cell Lung Cancer
por: He, Jiabei, et al.
Publicado: (2015)

An ensemble learning with active sampling to predict the prognosis of postoperative non-small cell lung cancer patients
por: Hu, Danqing, et al.
Publicado: (2022)

Genomic landscape and prognosis of patients with TP53-mutated non-small cell lung cancer
por: Fan, Zhisong, et al.
Publicado: (2022)

MARCH8 is associated with poor prognosis in non-small cell lung cancers patients
por: Fan, Jiye, et al.
Publicado: (2017)

Prevalence and correlation of anxiety and depression on the prognosis of postoperative non-small-cell lung cancer patients in North China
por: Huang, Xuan, et al.
Publicado: (2020)

Genomic characteristics in Chinese non-small cell lung cancer patients and its value in prediction of postoperative prognosis
por: Zhang, Bin, et al.
Publicado: (2020)

Evodiamine Stabilizes Topoisomerase I-DNA Cleavable Complex to Inhibit Topoisomerase I Activity
por: Chan, Agnes L.-F., et al.
Publicado: (2009)

‘LeishMan’ topoisomerase I: an ideal chimera for unraveling the role of the small subunit of unusual bi-subunit topoisomerase I from Leishmania donovani
por: Ganguly, Agneyo, et al.
Publicado: (2006)

Association between overexpression of Wip1 and prognosis of patients with non-small cell lung cancer
por: ZHAO, MIN, et al.
Publicado: (2016)

Cytoplasmic expression of G protein-coupled estrogen receptor 1 correlates with poor postoperative prognosis in non-small cell lung cancer
por: Li, Zhen-Hua, et al.
Publicado: (2022)

Expression of Cripto‐1 predicts poor prognosis in stage I non‐small cell lung cancer
por: Xu, Chunhua, et al.
Publicado: (2020)

The D-dimer level predicts the postoperative prognosis in patients with non-small cell lung cancer
por: Shiina, Yuki, et al.
Publicado: (2019)

Structural studies of type I topoisomerases
por: Baker, Nicole M., et al.
Publicado: (2009)

p16(INK4) Expression Is Associated with the Increased Sensitivity of Human Non‐small Cell Lung Cancer Cells to DNA Topoisomerase I Inhibitors
por: Fukuoka, Kazuya, et al.
Publicado: (1997)

Bacterial topoisomerase I and topoisomerase III relax supercoiled DNA via distinct pathways
por: Terekhova, Ksenia, et al.
Publicado: (2012)

Novel bivalent securinine mimetics as topoisomerase I inhibitors
por: Hou, Wen, et al.
Publicado: (2017)

Role of aneuploid circulating tumor cells and CD31(+) circulating tumor endothelial cells in predicting and monitoring anti‐angiogenic therapy efficacy in advanced NSCLC
por: Zhang, Tongmei, et al.
Publicado: (2021)

Reduced topoisomerase II activity in multidrug-resistant human non-small cell lung cancer cell lines.
por: Eijdems, E. W., et al.
Publicado: (1995)

Clinical significance of topoisomerase‐II expression in patients with advanced non‐small cell lung cancer treated with amrubicin
por: Sakurai, Reiko, et al.
Publicado: (2020)

Targeting of topoisomerases for prognosis and drug resistance in ovarian cancer
por: Bai, Yang, et al.
Publicado: (2016)

The modulation of topoisomerase I-mediated DNA cleavage and the induction of DNA–topoisomerase I crosslinks by crotonaldehyde-derived DNA adducts
por: Dexheimer, Thomas S., et al.
Publicado: (2008)

Cannot write session to /tmp/vufind_sessions/sess_qju95c9rpl0ol9rap1lhirsigo